Service revenue and European expansion drive the growth story
- TransMedics is trying to replace old cold storage with its Organ Care System for donor hearts, lungs, and livers.
- Q2 2026 revenue was $189.9 million, showing a strong recovery in net income to $14.7 million.
- The National Organ Program adds a logistics moat, but aircraft and staffing make the model harder to scale.
- The next test is whether CHOPS, Europe, and possible OPO bids can offset donor volume pressure and lower margins.
A bigger bet proving its leverage
TransMedics has built a rare position in transplant care. Its Organ Care System keeps donor organs warm and working outside the body, which can help transplant teams use more hearts, lungs, and livers. The company then wrapped that device business in the National Organ Program, or NOP, which handles organ retrieval and transport.
The bull case is that this becomes a hard-to-copy transplant network. Management is adding CHOPS, a cold-preservation device for short-transport hearts, building a European NOP with PAD Aviation, and preparing to bid on donor service areas tied to decommissioned U.S. organ procurement groups. Generating $14.7 million in net income during Q2 2026 shows this model can achieve profitability while scaling aggressive growth investments.
The bear case remains visible. Growth is real, yet margins face ongoing pressure as the company spends on Europe, new devices, aircraft, and staff. U.S. donor volumes also face friction because organ procurement organizations are reacting to the Transplant Modernization Act. If aggressive investments outpace revenue growth in future quarters, the valuation could shrink.
Devices plus the transplant road crew
TransMedics makes money in two main ways. First, it sells single-use disposable sets for each transplant that uses its OCS consoles. This is the razor-and-blade part of the model. The console can be reused, but the organ-specific set is used once.
Second, it sells services through the NOP. This gives transplant centers a fuller package of organ retrieval, clinical support, aircraft, and ground logistics. Service revenue can deepen customer ties, but it also brings flight operations, maintenance, hiring, and scheduling risk.
In Q2 2026, total revenue reached $189.9 million. The business is still mostly U.S. based. Europe is the next major expansion area, fueled by the closed investment in PAD Aviation, but it will likely cost money before it shows whether the U.S. model can travel successfully.
What TransMedics sells
OCS Heart
Warm perfusion system for donor hearts. It is part of the core FDA-approved OCS platform and is central to the company's transplant growth story.
OCS Lung
Warm perfusion system for donor lungs. It supports the same model of reusable consoles and single-use organ-specific disposable sets.
OCS Liver
Warm perfusion system for donor livers. Liver and heart case growth have been important drivers of NOP service revenue in recent filings.
Single-use disposable sets
These sets are required for each OCS transplant. They create recurring product revenue each time a center uses the system.
National Organ Program
NOP bundles organ retrieval, clinical support, and transport. It can make adoption easier for transplant centers, but it also makes TransMedics an aviation and logistics operator.
CHOPS
CHOPS is a controlled cold-preservation system aimed at short-transport donor hearts. The ENHANCE IDE supplement is under FDA review as of Q2 2026.
OCS Kidney Gen 3.0
Kidney is a future platform launch, not a current major revenue line in the provided filings. If successful, it would add a large new organ category to the OCS model.
Mix balances products and services
Segment mix reflects a blend of device sales and logistics services. In Q2 2026, total revenue reached $189.9 million. Sales remain heavily concentrated in the U.S. market, though international expansion is underway.
What could break the case
Donor volume shock
High impact · Medium oddsTransMedics depends on transplant volume. Management said U.S. deceased donor numbers have faced pressure due to friction tied to the Transplant Modernization Act. Fewer donor organs mean fewer OCS cases and less demand for NOP services.
NOP cost creep
High impact · Medium oddsThe NOP can be a moat, but it is complex. Aircraft, pilots, maintenance, dispatch, and clinical support add fixed costs. Management warned that PAD Aviation consolidation will dilute margins starting in the third quarter of 2026.
Europe rollout stalls
Medium impact · Medium oddsManagement wants to replicate the U.S. NOP model in Europe through PAD Aviation. That could expand the market, but Europe has different transplant systems, hospital buying patterns, and flight logistics. Slow adoption would make the upfront spending harder to defend.
CHOPS pricing disappoints
Medium impact · Medium oddsCHOPS targets cold static storage, especially short-transport donor hearts. That market may have different pricing and margin than OCS warm perfusion. If CHOPS wins volume but earns low margins, it may add revenue without much profit.
OPO bid uncertainty
Medium impact · Medium oddsTransMedics wants to bid for donor service areas linked to decommissioned organ procurement organizations if CMS allows for-profit bidders. This could give the company deeper control of the transplant chain. It could also require large capital outlays and new operating duties.
In one breath
What does TransMedics do?
TransMedics makes systems that preserve donor organs for transplant. Its OCS platform keeps hearts, lungs, and livers warm and perfused, and its NOP helps move organs from donors to transplant centers.
How does TransMedics make money?
It sells single-use disposable sets used with OCS consoles, and it sells logistics and clinical services through the NOP. In Q2 2026, total revenue reached $189.9 million.
Why did the TransMedics thesis change in 2026?
Management is spending heavily on Europe, CHOPS, Gen 3.0 work, and aviation while U.S. donor volumes are under pressure. However, Q2 2026 results showed a return to solid net income, suggesting the model can handle the investment load.
What is CHOPS?
CHOPS is TransMedics' Controlled Hypothermic Organ Preservation System. It is aimed at cold storage use cases, especially short-transport donor hearts, and could expand the company beyond warm perfusion.
